Janux Therapeutics Taps Dr. William Go as Chief Medical Officer

Janux Therapeutics Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel immunotherapies, has appointed William Go, M.D., Ph.D., as its Chief Medical Officer (CMO).

Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the company to pursue other opportunities.

“Janux is entering an important new phase as our programs advance and the complexity of our clinical and regulatory efforts increases,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “Will brings a combination of early- and late-stage development experience, regulatory leadership, and launch execution that will strengthen our organization as we scale.”

Experience

Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-in-class launches. He joins Janux at an important stage as the company advances its pipeline and continues to scale its clinical and regulatory operations.

Most recently, Go served as Chief Medical Officer at A2 Biotherapeutics, where he led development of logic-gated CAR T-cell therapies for solid tumors. Previously, he held senior leadership roles at Kite Pharma, where he led the pivotal ZUMA-1 trial supporting the FDA and EMA approvals of YESCARTA. Following Kite’s acquisition by Gilead Sciences, he continued in a senior clinical development leadership role overseeing programs in large B-cell lymphoma.

Earlier in his career at Amgen, Go contributed to the global label expansion of Vectibix and helped advance extended RAS next-generation sequencing strategies in colorectal cancer to identify predictive biomarkers.

Go earned a B.A. in Biology from Carleton College and completed an M.D. and Ph.D. through the UC San Diego Medical Scientist Training Program. He completed residency training in internal medicine and a fellowship in hematology/oncology at UC San Diego, with tumor immunology research supported by fellowships from the California Institute for Regenerative Medicine and the American Association of Cancer Institutes.

“What attracts me to Janux is the strength of its science and the breadth and depth of its oncology pipeline, anchored by a differentiated, tumor-activated T-cell engager platform,” Go said. “Janux is tackling important clinical challenges with programs designed to build on existing standards of care, and I believe the company is well positioned to deliver meaningful advances for patients. I’m excited to work with the Janux team, investigators, and partners as we move these programs forward.”

More Janux News

Janux Therapeutics and Bristol Myers Squibb (BMS) announced recently that they will develop a novel, tumor-activated therapeutic in an exclusive worldwide licensing agreement.